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In spite of major recent advances in diffuse intrinsic pontine glioma (DIPG) molecular
characterization, this body of knowledge has not yet translated into better treatments.
To date, more than 250 clinical trials evaluating radiotherapy along with conventional
cytotoxic chemotherapy as well as newer biologic agents have failed to improve the dismal
outcome when compared to palliative radiation alone. The biology of DIPG remained
unknown until recently when the neurosurgical expertise along with the recognition by the
scientific and clinical community of the importance of tissue sampling at diagnosis; ideally,
in the context of a clinical trial and by trained neurosurgical teams to maximize patient
safety. These pre-treatment tumor samples, and others coming from tissue obtained
post-mortem, have yielded new insights into DIPG molecular pathogenesis. We now
know that DIPG comprises a heterogeneous disease with variable molecular phenotypes,
different from adult high-grade glioma, other non-pontine pediatric high-grade gliomas,
and even between pontine gliomas. The discovery of histone H3.3 or H3.1 mutations has
been an important step forward in understanding tumor formation, maintenance, and
progression. Pharmacologic reversal of DIPG histone demethylation therefore offers an
important potential intervention strategy for the treatment of DIPG. To date, clinical trials
of newly diagnosed or progressive DIPG with epigenetic (histone) modifiers have been
unsuccessful. Whether this failure represents limited activity of the agents used, their
CNS penetration, redundant pathways within the tumor, or the possibility that histone
mutations are necessary only to initiate DIPGs but not maintain their growth, suggest
that a great deal still needs to be elucidated in both the underlying biology of these
pathways and the drugs designed to target them. In this review, we will discuss the role
of both epigenetic and genetic mutations within DIPG and the development of treatment
strategies directed against the unique abnormalities present in this disease.
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Introduction
Diffuse intrinsic pontine glioma (DIPG), the most frequent brainstem tumor in pediatrics, is one
of the deadliest cancers among children. Until recently, diagnosis has been based on classic clinical
and radiological presentation, with “no indication” for histologic confirmation in the vast majority
of cases (1). This practice – with obvious absence of tumor tissue at diagnosis to study – has
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left DIPG basic and translational research behind other brain and
non-CNS pediatric tumors in terms of their molecular character-
ization (2). Involved field radiation therapy of 54–60Gy directed
to the infiltrated pons, fractionated over a 6-week period, is the
only palliative treatment that effectively, albeit temporarily, delays
the progression of tumor growth, with improvement of most of
the symptoms in approximately 70–80% of the cases. No survival
benefit has been identified with alternative radiation strategies
(i.e., hyper- or hypo-fractionation) versus conventional radiation.
Similarly, radiation sensitization with different agents has been
attempted without any improvement in outcome (1, 3). Unfortu-
nately, themajority of children affected byDIPGwill progress dur-
ing the first year after diagnosis and only approximately 10% will
survive past the second year. At tumor progression, no effective
salvage therapy is available; although re-irradiation may provide
transient benefit in a subset of patients (4). To date, more than 250
clinical trials including standard chemotherapeutic agents admin-
istered in different intensities and timings, biologic and targeted
agents, immunotherapy, etc., along with radiation therapy have
not significantly improved the event free survival (EFS) or overall
survival (OS) of patients with DIPG (2). Not only have patients
and their families not benefited from these therapies but also
have suffered undesirable side effects of these futile interventions.
Thus, with the increasing biologic data, we have now on DIPG,
the scientific and clinical communities have the ability to start
selecting more rationale treatment options that take into account
the underlying pathways driving these tumors, the penetration
of drugs into the tumor and the potential resistance pathways
generated by the tumor (5).
Recent Biologic Discoveries in DIPG
In the last decade, considerable efforts in revealing the cell of
origin and underlying molecular make up of DIPG by different
collaborative groups have yielded major discoveries at the genetic
and epigenetic levels. Monje et al. proposed a Nestin+/Vimentin+
neural pontine precursor-like cell as a candidate for DIPG cell of
origin, linked both anatomically – restricted to the ventral pons –
and temporally to the incidence of DIPG. Additionally, the same
group proposed that dysregulation of the Hedgehog pathway is
of relevance in tumor development (6). At the molecular level, a
considerable bulk of DIPG knowledge comes from biologic stud-
ies obtained from post-mortem series and also from the initiative
of several groups, first by the French, in obtaining tumor tissue
through stereotactic biopsies at diagnosis (6, 7). This procedure, in
expert hands and in highly controlled circumstances, has shown
to be safe with no mortality reported and limited associated mor-
bidity (8–10). Of note, it must be emphasized that not all patients
are appropriate to undergo a biopsy, not all neurosurgeons have
the experience to perform these procedure, and not all institutions
have the molecular pathology expertise or experience to obtain
meaningful data from these very small, heterogeneous, and pre-
cious samples (1). In circumstances where biopsy is appropriate,
deep molecular investigation of these samples – by whole genome
sequencing, gene expression array, and DNA methylation array –
have resulted in our ability to define DIPG in “biologic terms”
rather than in merely radiologic or clinical ones (8).
Diffuse intrinsic pontine gliomas have a high frequency
(around 80%) of mutually exclusive somatic mutations of H3F3A
and HIST1H3B genes, resulting in replacement of lysine 27 by
methionine (K27M) in the encoded histone H3.3 and H3.1. Inter-
estingly, other pediatric midline high-grade gliomas share muta-
tions in H3.3 but not the H3.1 mutations and cortical pediatric
and adult malignant gliomas rarely share these mutations (11).
The identification of these prevalent mutations in DIPG not only
helps confirm the diagnosis at a molecular level but has also
shown to provide relevant clinical and prognostic information in
independent retrospective series. For example, H3.3 mutations
are associated with shorted survival compared to H3.1 mutations.
H3.1 mutated tumors tend to occur in younger patients and are
often associated with other specific mutations (i.e., ACVR1) that
are not observed in other midline or cortical malignant gliomas
(8, 12–14). Other alterations that appear important in DIPG are
mutations in TP53 – identified in 60% of cases – PI3K, EGFR,
PTEN, ATRX, and PDGFRA (7, 14–17). Thus, it is now clear that
DIPG is different at themolecular level from other non-brainstem
high-grade gliomas and other types of pediatric brain tumors.
To go even further, we now appreciate that DIPG is not a single
entity, but rather a complex and varied pathology comprised of
separate molecularly defined sub-groups that share clinical and
radiological features, as well as a grim prognosis. Moving forward,
the development of new clinical trials should take into account
the heterogeneity of DIPG, not only among different patients but
also within different areas of the tumor of each patient, which
may play a key role in tumor resistance to current therapies. The
ability to detect histone mutations using immunohistochemical
analysis of paraffin embedded formalin fixed tissue rather than
more completedmolecular sequencing should simplify our ability
to identify these important patient subpopulations (18).
Epigenetic Alterations in DIPG
Gliomagenesis: “The Polycomb
Connection”
The role of epigenetic modifications in tumorigenesis, tumor
maintenance, and progression has gained a lot of momentum in
recent years, but has not yet been well established (19). Certainly,
epigenetic changes, either alone or in combination with other
mutations, may need to work in concert to drive cancer initi-
ation, propagation, or both. This has led to a growing interest
in identifying the specific role that epigenetic alterations play in
DIPG and the potential effect of epigenetic modification as a
way to treat and alter the natural history of this deadly cancer
(11, 20). Recently, the mutation of the H3F3A gene has gained
considerable attention for its potential role in tumorigenesis, and
therefore, as a good candidate for targeted therapy. As mentioned
above, approximately 80% of DIPG tumors contain mutations in
genes that encode histones (H3.3 or H3.1), proteins that package
DNA into chromatin. These mutations, which change lysine 27 to
methionine (K27M), are believed to sequester polycomb repres-
sive complex 2 (PRC2), which normally represses gene expression
through histone methylation. When PRC2 is functionally inacti-
vated, genes that should be silent are expressed, which is thought
to drive cell transformation (Figure 1A). These alterations abolish
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FIGURE 1 | (A) In DIPG, there is global hypomethylation of Lys27 of H3, which
promotes a more accessible chromatin state characterized by H3K27
acetylation and aberrant gene expression. Histone H3.1 or H3.3 harbors a
K27M aberration. The mutant K27 histone inhibits PRC2, which is the major
H3K27 methylase. (B) Treatment of DIPG with an epigenetic modifier – in the
cartoon GSKJ4 – restores methylation at H3K27 toward the physiological state,
causing tumor shrinkage. Reprinted by permission from Macmillan Publishers
Ltd: Nature Genetics [May; 46(5):457–61], copyright 2014.
a crucial site of regulatory post-translational methylation (PTM)
(13, 21, 22). As such, tumor-derived histone gene mutations are
thought to drive tumorigenesis in very specific cell lineage and
developmental context by causing reduced histone K27 methyla-
tion and thereby altering gene expression in cells of the developing
ventral pons. Interestingly, it is well known that the introduction
of the H3.3K27M mutation into p53-null and nestin-expressing
progenitors in the neonatal mouse brainstem is unable to generate
gliomas, although it is sufficient to induce ectopic cell clusters in
the mouse brain. This has led different groups to focus on the
role that these epigenetic alterations play inDIPG initiation versus
maintenance or proliferation (10, 12, 17, 18, 22). One model of
DIPG was generated by differentiating human embryonic stem
cells into neural progenitor cells and then transducing them with
a viral vector carrying the gene encoding H3.3K27M. The expres-
sion of this gene was mitogenic only in neural progenitors derived
from embryonic stem cells, and not in undifferentiated embryonic
stem cells or astrocytes derived from these cells. This suggested
that the histone mutation is oncogenic only in the appropriate
cell type and cellular context. Importantly, only when progenitors
also expressed an activated form of PDGFRA and lacked the TP53
tumor suppressor could they give rise to gliomas after injection
into the brainstem of mice. Moreover, even with all three genetic
alterations present, the tumors grew slowly and lacked histolog-
ical features of high-grade glioma (i.e., palisading necrosis and
vascular proliferation) (23).
Recently, the effect of pharmacologic modulation of histone
K27 methylation, by inhibiting H3K27 demethylation, has been
demonstrated. The rational used was the following: by inhibit-
ing the activity of JMJD3 H3K27 demethylase, K27 methylation
would increase with a subsequent decrease in gene expression.
The expected result was to inhibit cell proliferation in the K27M
mutant DIPG cell lines derived from patient’s tumors. The use of
the GSKJ4, an inhibitor of JMJD3 H3K27 demethylase in K27M-
expressing cells revealed a dose-dependent inhibition of cellular
viability, with 50% growth inhibition. GSKJ4 also led to more
apoptosis of K27M-expressing cells and completely inhibited the
clonal growth of all K27M-expressing cells. Similar results were
obtained from in vivo experiment with the use of athymic (nu/nu
genotype, BALB/c background) mice harboring brainstem K27M
glioma xenografts. The drug showed significant reduction in the
growth of K27M tumors engrafted in mouse brainstem and sig-
nificantly extended animal survival with evidence of decreased
proliferation and augmented apoptosis (Figure 1B). Drug showed
good brain penetration including to the site of brainstem tumor
development. According to the gene expression analysis, GSKJ4
treatment seemed to up-regulate the genes involving with apop-
tosis, cell cycle arrest, and cell differentiation, and down-regulate
the genes involving with angiogenesis and cell proliferation (24,
25). It is of interest, and potential significance, that another recent
study identified JMJD3 as a potential therapeutic target in treating
T-cell acute lymphoblastic leukemia (T-ALL), in which JMJD3
expression is also elevated (26). Results from this study, in com-
bination with results involving the inhibition of JMJD3 in DIPG,
suggest that JMJD3 as an emerging therapeutic target in cancer
treatment. More recently, Grasso et al. took a different approach
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integrating genomic and chemical screening data. By chemical
screening using a DIPG culture panel, they identified panobinos-
tat as one of themost active agents in the screen (27). Encouraging
results in pre-clinical testing in cell lines and animalmodels of this
FDA-approved potent HDAC inhibitor will likely take this drug
to clinical trials soon. Interestingly, cell culture testing showed
that there was synergy with the combination of panobinostat with
GSKJ4 – and not with other tested drugs – depicting the relevance
of identifying the appropriate drug combination for increasing the
likelihood of clinical benefit (27).
Future Directions and Implications in DIPG
Clinical Trials Design
The discovery of K27Mmutations in DIPGwas an important step
forward in understanding this tumor and promises to yield new
approaches to treating the disease. However, several key aspects
should be taken into account when designing future clinical trials
for DIPG (Box 1). Historically, epigenetic modification (even
before the discovery of the high prevalence of histonemutations in
DIPG) with valproic acid, a drug that theoretically penetrates the
blood–brain barrier, has been unsuccessful inmost series (28). It is
likely that this failure represents lack of effective drug levels in the
CNS, off target activity, or alternative escaping pathways within
the tumor. The COG ACNS0927 phase 1/2 clinical trial – cur-
rently closed to accrual – that tested suberoylanilide hydroxamic
acid (SAHA, Vorinostat), a histone deacethylase inhibitor, and
local irradiation, followed bymaintenance SAHA in children with
newly diagnosed DIPG, will show if this more potent epigenetic
modifier has some impact on EFS and OS in DIPG. It is clear
that we need to better understand what are the relevant and key
pathways and how we can better target them (1, 2). The scientific
community needs to continue working to create models that can
be used to study DIPG biology and demonstrate that thesemodels
can be useful in identifying novel and more effective therapies.
It seems that epigenetic regulation may play a key role in tumor
formation and maintenance. Thus, it makes sense that drugs tar-
geting these mechanisms will be ideal for testing in these models.
However, these agents should meet the following requirements:
they should inhibit the target, be delivered to the pons in effective
concentrations with sufficient duration of exposure, and have an
acceptable toxicity profile, taking into account the continuing
normal development of pediatric patients with DIPG. Other con-
siderations that need to be taken into account in the identification
of optimal drug therapy include a detailed understanding of the
target, when and where it is present within the tumor and on
what other normal cell populations does it have important impact.
Finally, understanding how best to measure clinical efficacy of
novel agents using changes in the tumor on imaging, as well as
the traditional measures of PFS and OS need to be determined.
All these questions should be addressed before launching the next
wave of clinical trials in order to decrease the likelihood of addi-
tional negative results (2). With the ongoing clinical trials, which
include tumor biopsy at diagnosis, some of these questions will
hopefully be answered. While a strong positive improvement in
survival is optimal, it is critical that clinical trials that are negative
have an ability to understand why the treatment did not work.
BOX 1 Key points in designing “epigenetic” future clinical trials for
DIPG.
 The identification of epigenetic dysregulation in DIPG pathogenesis opens
new avenues in treating this disease.
 Prior “negative” clinical trials may represent lack of effective drug levels in
the CNS, off target activity, or alternative escaping pathways within the
tumor.
 Pre-clinical testing in representative cell cultures and appropriate animal
models can be useful in identifying novel and more effective therapies.
 An ideal drug should be delivered in effective concentrations and inhibit
the target, with sufficient duration of exposure, and have an acceptable
toxicity profile.
 Early identification of responders by newer imaging techniques or biologic
surrogates may avoid futile toxicities and unfulfilled hopes.
 Re-biopsy at time of progression should be considered in the near future
(once safety issues are addressed), since the driving target identified in
the tumor at diagnosis – and directing therapy – may be gone or altered
at progression.
 Novel clinical trial design and combination of agents with different mech-
anism of action may offer a better chance for tumor control in this deadly
entity.
Molecular profiles have proven to be prognostic and biomarkers
for treatment options are now a real possibility. Selecting patients
by specific genetic and epigenetic alterations as eligibility criteria
for clinical trial enrollment needs to be considered. Unfortunately,
the molecular advances made to date and identification of path-
ways mutated in these tumors has not resulted in improvement
in either PFS or OS. One consideration that could address some
of the disappointment in response to targeted therapy to date
is re-biopsy at the time of progression, not just at autopsy as is
now commonly performed. Tumor evolution and resistant clone
selection are recognized phenomena in cancer biology and it is
likely that these may play a role in DIPG treatment resistance
and rapid tumor progression. Re-analysis of tumor tissue at pro-
gression may be needed to assess for the genetic and epigenetic
changes over the pre-therapy sample, while also identifying “new”
target engagement after exposure to a specific inhibitor or combi-
nation of inhibitors. With paired molecularly characterized tumor
tissue (at diagnosis and after treatment) target modulation and
engagement could be potentially more effectively achieved. If the
scientific community decides to go down this path, the safety
of the procedure will have to be analyzed first by teams with
expertise in the field. The application of innovative approaches
for upcoming clinical trials will be paramount in identifyingmore
effective therapies. Importantly, combination phase I trials in
oncology have shown to be feasible and safe (29). This strategy
may decrease the time elapsing from drug development to drug
testing in patients, increasing the number of drugs tested in a given
period. Also, newer biologic targeted agents’ activity – including
epigenetic modifiers – relies more on their “biologic effect,” rather
than on its “dose effect,” with no need of escalating to themaximal
tolerated dose (19). Therefore, the expected toxicity with each
drug or combination of drugs is lower when compared with trials
that include classic cytotoxic agents.
Many questions remain to be answered in the understanding of
this disease, including the cancer stem cell and appropriate context
for DIPG initiation, as well as which mutations and epigenetic
alterations contribute to tumormaintenance and progression. The
high incidence and exclusivity of histone H3 mutations to DIPG
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highlights the importance of identifying the true cell of origin
that is susceptible to these mutations, as well as how the sig-
naling pathways cooperate to drive gliomagenesis in a specific
developmental context. It is now well recognized that epigenetic
changes influence many of the hallmarks of cancer, such as
malignant self-renewal, differentiation blockade, evasion of cell
death, and tissue invasiveness (11, 30). Thus, it is reasonable
that future clinical trials should include epigenetic modifiers at
least as part of the therapeutic schema. It is hoped that nor-
mal cells will not be significantly affected by epigenetic modi-
fiers and thus may be well tolerated in pediatric patients. The
“epigenetic vulnerability” of certain cancer cells in many ways
mirrors the age old axiom of “oncogene addiction.” Some cancer
cells are reliant on specific epigenetic pathways, whereas normal
cells have alternative compensating pathways that protect them
from these inhibitors (19). Further studies that address these
and other questions will ultimately lead to more effective treat-
ments for DIPG. Given the dismal prognosis associated with
this disease, there will be strong incentive to move new treat-
ments forward into clinical trials, but with a novel approach. It
is likely that the key for more effective therapies will include
“combination therapies.” It is likely that many of these new epi-
genetic drugs offer synergistic benefits, and may also synergize
with other targeted agents. This “combination” approach will not
only potentially increase therapeutic efficacy but also reduce the
likelihood of drug resistance with higher chances for durable
tumor control at presentation and hopefully one day result in
a cure.
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